DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main Has $14.58 Million Stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 17.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 346,597 shares of the biopharmaceutical company's stock after buying an additional 51,874 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main owned about 0.38% of Ultragenyx Pharmaceutical worth $14,581,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Norges Bank acquired a new position in Ultragenyx Pharmaceutical in the 4th quarter worth about $40,463,000. Deep Track Capital LP acquired a new position in Ultragenyx Pharmaceutical during the fourth quarter worth $27,493,000. Pictet Asset Management Holding SA raised its holdings in Ultragenyx Pharmaceutical by 125.5% during the fourth quarter. Pictet Asset Management Holding SA now owns 1,173,638 shares of the biopharmaceutical company's stock valued at $49,375,000 after buying an additional 653,088 shares in the last quarter. First Trust Advisors LP boosted its stake in shares of Ultragenyx Pharmaceutical by 3,097.1% during the 4th quarter. First Trust Advisors LP now owns 544,202 shares of the biopharmaceutical company's stock worth $22,894,000 after acquiring an additional 527,180 shares in the last quarter. Finally, Alyeska Investment Group L.P. raised its stake in shares of Ultragenyx Pharmaceutical by 23.1% in the 4th quarter. Alyeska Investment Group L.P. now owns 1,439,740 shares of the biopharmaceutical company's stock valued at $60,570,000 after acquiring an additional 269,733 shares in the last quarter. 97.67% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

RARE has been the topic of a number of recent analyst reports. Canaccord Genuity Group lifted their price target on shares of Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the company a "buy" rating in a research report on Tuesday, February 18th. Piper Sandler dropped their target price on shares of Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an "overweight" rating on the stock in a report on Monday, March 17th. Morgan Stanley boosted their target price on shares of Ultragenyx Pharmaceutical from $64.00 to $65.00 and gave the stock an "overweight" rating in a research report on Friday, May 9th. JPMorgan Chase & Co. raised their price target on Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the company an "overweight" rating in a research report on Thursday, March 27th. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $118.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, February 26th. One investment analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to data from MarketBeat.com, Ultragenyx Pharmaceutical has an average rating of "Moderate Buy" and a consensus target price of $90.93.

Insider Activity at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis sold 25,000 shares of the company's stock in a transaction on Friday, February 28th. The stock was sold at an average price of $42.48, for a total transaction of $1,062,000.00. Following the transaction, the chief executive officer now owns 2,158,985 shares of the company's stock, valued at approximately $91,713,682.80. This represents a 1.14% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Karah Herdman Parschauer sold 2,990 shares of Ultragenyx Pharmaceutical stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $42.88, for a total value of $128,211.20. Following the completion of the sale, the executive vice president now owns 54,991 shares of the company's stock, valued at approximately $2,358,014.08. The trade was a 5.16% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 125,405 shares of company stock valued at $5,285,169 in the last ninety days. Insiders own 5.50% of the company's stock.

Ultragenyx Pharmaceutical Trading Down 2.4%

NASDAQ RARE traded down $0.85 on Wednesday, reaching $34.55. The company's stock had a trading volume of 225,157 shares, compared to its average volume of 826,923. Ultragenyx Pharmaceutical Inc. has a 52 week low of $29.59 and a 52 week high of $60.37. The firm has a market cap of $3.27 billion, a PE ratio of -5.45 and a beta of 0.34. The business has a 50-day moving average price of $36.67 and a 200 day moving average price of $42.11.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last posted its earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.57) EPS for the quarter, missing the consensus estimate of ($1.54) by ($0.03). Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. The company had revenue of $139.29 million for the quarter, compared to the consensus estimate of $145.98 million. During the same quarter last year, the business earned ($2.03) EPS. Ultragenyx Pharmaceutical's quarterly revenue was up 28.0% compared to the same quarter last year. Analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current fiscal year.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.